Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]

Affiliations

• ¹ Department of Medicine, Memorial Sloan-Kettering Center, New York, USA. Electronic address: jhaverik@mskcc.org.
• ² Biostatistics, E-A Biostatistical Center, Boston, USA.
• ³ Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA.
• ⁴ Knight Cancer Institute, Oregon Health Science University, Portland, USA.
• ⁵ Medical Oncology, Thomas Jefferson University, Philadelphia, USA.
• ⁶ Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.
• ⁷ Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA.
• ⁸ Department of Biostatistics, Dana Farber Cancer Institutes, Boston, USA.
• ⁹ Biometric Research Branch, National Cancer Institute, Bethesda, USA.
• ¹⁰ Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda, USA.
• ¹¹ Center for Biomedical, Informatics & Information Technology, National Cancer Institute, Bethesda, USA.
• ¹² Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, USA.
• ¹³ Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA.
• ¹⁴ Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.
• ¹⁵ Department of Internal Medicine, University of Texas Southwestern, Dallas, USA.
• ¹⁶ University of Pennsylvania, Philadelphia, USA.
• ¹⁷ CTEP, National Cancer Institute, Bethesda, USA.
• ¹⁸ Cancer Center, Massachusetts General Hospital, Boston, USA.